NPO Petrovax Pharm is a leading research and manufacturing company in Russia, producing pharmaceuticals and vaccines. Interros acquired a controlling stake in the company in 2013.
The company was founded in 1996 by a team of Russian researchers to develop, produce and commercialize original innovative pharmaceuticals.
The company’s main areas of focus are manufacturing flu vaccine to meet the national immunization calendar, and developing and producing immunobiologicals and long-acting nanobio drugs.
The company’s product line consists exclusively of innovative drugs and vaccines that NPO Petrovax Pharm successfully markets in Russia and the countries of the CIS and the EU.
February: Petrovax Pharm signs a trilateral strategic cooperation agreement in order to localize production of the Russian flu vaccine Grippol® Plus in Iran.
Petrovax Pharm launches Imoferaza®, an innovative ointment to treat problem areas and scar tissue after injuries, burns, acne, surgeries, and cosmetic procedures.
June: Petrovax Pharm and the German firm Boehringer Ingelheim sign an agreement to localize in Russia the full production cycle of state-
July: Petrovax Pharm receives a Russian GMP compliance certificate following a directive of the Russian Federation Ministry of Industry and Trade.
August: Petrovax Pharm exports 1.5 million doses of Grippol® Plus flu vaccine to Kazakhstan.
October: Petrovax Pharm supplies more than 8.5 million doses of pediatric Grippol® Plus flu vaccine to meet the National Vaccination Schedule of the Russian Federation.
Polyoxidoniy, manufactured by Petrovax Pharm, receives a 2016 Russian Pharma Award for best pediatric immunity booster for acute upper respiratory infections.
Petrovax Pharm supplies 1.5 million doses of Grippol® Plus to Kazakhstan under the national drug and medical supplies procurement program.